- Home
- ACAD vs BVN Comparison
ACAD vs BVN Comparison
Compare ACAD & BVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- BVN
- Stock Information
- Founded
- ACAD 1993
- BVN 1953
- Country
- ACAD United States
- BVN Peru
- Employees
- ACAD N/A
- BVN N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- BVN Metal Mining
- Sector
- ACAD Health Care
- BVN Basic Materials
- Exchange
- ACAD Nasdaq
- BVN Nasdaq
- Market Cap
- ACAD 4.0B
- BVN 4.2B
- IPO Year
- ACAD 2004
- BVN 1996
- Fundamental
- Price
- ACAD $25.99
- BVN $19.15
- Analyst Decision
- ACAD Buy
- BVN Buy
- Analyst Count
- ACAD 20
- BVN 2
- Target Price
- ACAD $28.63
- BVN $16.75
- AVG Volume (30 Days)
- ACAD 2.0M
- BVN 958.7K
- Earning Date
- ACAD 08-06-2025
- BVN 10-29-2025
- Dividend Yield
- ACAD N/A
- BVN 1.53%
- EPS Growth
- ACAD 615.00
- BVN 436.33
- EPS
- ACAD 1.33
- BVN 1.98
- Revenue
- ACAD $1,018,885,000.00
- BVN $1,307,905,000.00
- Revenue This Year
- ACAD $14.01
- BVN $15.88
- Revenue Next Year
- ACAD $11.72
- BVN $8.52
- P/E Ratio
- ACAD $19.61
- BVN $9.60
- Revenue Growth
- ACAD 14.41
- BVN 32.24
- 52 Week Low
- ACAD $13.40
- BVN $11.50
- 52 Week High
- ACAD $26.65
- BVN $19.24
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- BVN 64.36
- Support Level
- ACAD $25.14
- BVN $18.37
- Resistance Level
- ACAD $26.65
- BVN $18.99
- Average True Range (ATR)
- ACAD 0.67
- BVN 0.42
- MACD
- ACAD 0.04
- BVN 0.01
- Stochastic Oscillator
- ACAD 70.27
- BVN 92.68
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.